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Growth hormone-releasing hormone (GRH) was initially isolated, characterized, sequenced,
and cloned from human tumors and subsequently from the hypothalamus of humans and other
animal species. Extensive structure-function studies have indicated the amino terminus to be
most important for its biologic action, and the primary mechanism of its bioinactivation occurs
by cleavage of an amino terminal dipeptide. The GRH gene is expressed primarily in the
hypothalamic arcuate nucleus but also in the placenta. Expression of the GRH gene is regulated
by growth hormone in a classical feedback manner, with hypophysectomy leading to increased
expression that is reversed by growth hormone treatment. GRH geneoverexpression in transgenic
mice leads to a syndrome similar to that of ectopic GRH secretion with massive pituitary
hyperplasia and markedly enhanced growth. The transgenic mouse has been used for studies of
GRH biosynthesis and provides a suitable model for the study of precursor processing to the
mature hormone.
ISOLATION AND CHARACTERIZATION OF GRH
The concept of a growth hormone (GH)-releasing hormone (GRH) was first
proposed in the early 1960s and evidence for its existence appeared later in the same
decade (see [I] for review). Although GH-releasing activity in hypothalamic tissue
extracts was demonstrated by several laboratories [2,3], isolation of GRH from the
hypothalamus proved to be a formidable task. The isolation and sequencing of GRH
first occurred as a result of the clinical recognition that a GH-releasing factor was
being secreted by extra-pituitary tumors associated with acromegaly [4,5]. Identifica-
tion of two such tumors (both of pancreatic islet origin) with high levels ofactivity led
to the definitive characterization of GRH as a 44 amino acid peptide in 1982 [6,7].
Three forms of GRH were isolated from the tumors (GRHI,4NH2, GRHI4oOH, and
GRHI,370H) with GRHI-40OH actually being the most abundant form. Shortly
thereafter, GRH was identified in human hypothalamus [8] and its sequence was
shown to be identical to that found in the human tumors [9]. Both the 1-40 and 1-44
forms of the hormone were shown to exist in human hypothalamus. Based on the
structure of GRH, oligonucleotide probes were constructed, the cDNA for human
GRH was reported by two different groups [10,11], and, shortly thereafter, the entire
GRH gene cloned [12].
The human genome contains only a single GRH gene with a length ofapproximately
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FIG. 1. Schematic representations of
the human GRH gene, cDNA, and
precursor peptide. The coding sequence
for the mature peptide is contained in
exons 3 and 4, while the signal peptide
and C terminal peptide extension are
contained in exons 2 and 4-5, respec-
tively.
10 kilobases (Fig. 1). The gene contains five exons resulting in a mRNA species,
including the polyadenylation signal, ofabout 750 bases. Two nearly identical mRNAs
have been reported, which differ only in a slight alteration ofthe splice site ofthe fifth
exon, resulting in the absence of a single serine near the 3' end ofthe coding region. The
mRNA codes for a precursor peptide of 107 (or 108) amino acids, consisting of a
characteristic signal peptide, the 44 amino acid GRH, and a 30 (or 31) amino acid C
terminal peptide. The last two splice sites occur in the N terminal halfof GRH and in
the middle ofthe C terminal peptide and explain some ofthe species variation observed
in primary sequence, particularly in rodents.
The structure ofGRH has now been reported in several other species [1] and varies
only minimally from the human hormone in most of the larger animals studied. In
contrast, rat GRH, the second species in which the cDNA sequence has been
published, exhibits considerable dissimilarity with human GRH (only 68 percent
homology). Even more extenisve differences occur in the C terminal peptide (deduced
from the structure of rat GRH mRNA) [13] where the carboxy terminal half of the
peptide is completely dissimilar, a change explained by an alteration in the splice site of
the fifth exon. It was anticipated that mouse GRH would resemble rat GRH more
closely that human GRH, since rat GRH exhibits greater GH-releasing potency (60
percent) than does human GRH in primary cultures of mouse pituitaries [1]. Recent
data indicates that the sequence of mouse GRH exhibits comparable homology with
human and rat GRH, though comparison of its C terminal peptide suggests a greater
evolutionary association with rat than with human GRH [14].
The biologic activity of GRH appears to be centered around the amino terminal
region of the peptide, and the presence of tyrosine or histidine in position one is
essential for receptor binding [9,15]. In contrast, the C terminal third of the molecule
is not essential andGRHI 29NH2 exhibits full biologic potency in vivo and in vitro. This
pattern is thus similar to that of ACTH, where full biologic activity is present in the
first 24 of the peptide's 39 amino acid residues. As with ACTH, species variability is
greater in the carboxy than the amino terminal region. Current attempts to develop
superanalogs are therefore based on using GRHI 29NH2 as the parent compound. In a
single study, the biologic activity of the C terminal peptide has been examined and
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shown to alter food intake after central nervous system administration in the rat [16].
It is not known, however, whether this observation has physiologic relevance.
GRH METABOLISM
Detailed studies ofthe metabolism ofhuman GRH in vivo and in vitro [17-19] have
shown that the major mechanism for enzymatic destruction occurs by cleavage of the
amino terminal dipeptide by a plasma enzyme, dipeptidylpeptidase, type IV. This
enzymatic conversion occurs rapidly; the first and second components of the plasma
disappearance rate for GRH are 1.0 and 6.8 minutes, respectively [18]. The product,
GRH344NH2, is biologically inactive, thus ensuring that GRH action is limited to
a single pass phenomenon. This degradation process is also of importance in the
metabolism ofexogenously injected GRH, and the structural modification of GRH to
create dipeptidylpeptidase resistance has been a critical requirement in the develop-
ment of superactive GRH analogs [19]. GRH contains several sites of potential
cleavage by trypsin-like endopeptidases and evidence for a GRH12,4 fragment has also
been reported [19].
GRH GENE EXPRESSION
The development ofsensitive methods for measurement ofGRH mRNA in extracts
of hypothalamus has been followed by the accumulation of data concerning the
regulation of GRH gene expression. The anatomic sites ofGRH gene expression were
predicted by previous immunocytochemical studies with anti-GRH serum [20,21]. To
date, GRH mRNA has been identified only in the arcuate nucleus of the hypothala-
mus and in the placenta ([22]; [Downs TR, Chomczynski P, Frohman LA: unpub-
lished observations]). A considerably larger (1.9 kb) mRNA species that hybridizes to
the rat GRH mRNA probe has been reported in rat testis [23], though the GRH
peptide has not been detected in this organ and the significance ofthis finding remains
to be determined.
Target organ hormone (GH) removal by hypophysectomy results in a marked
increase in hypothalamic GRH mRNA levels in the rat [22,24]. This change is seen
within three days ofhypophysectomy and persists for at least six weeks (Fig. 2). There
is a concomitant decrease in GRH content in the hypothalamus, a phenomenon that is
only partially explained by the slight increase in GRH release observed in vitro
[24,25]. The possibility of an impairment in post-transcriptional control has been
suggested [24], though it remains to be proven. A parallel set of findings has recently
been observed with preproTRH [26]. Adrenalectomy and gonadectomy, alone or in
combination, do not result in any changes in hypothalamic GRH mRNA levels [24].
Treatment ofhypophysectomized animals with GH alone or in combination with other
target organ hormones decreases hypothalamic GRH mRNA levels and increases
GRH peptide content, supporting the role of GH in the regulation of GRH gene
expression. It is not presently known whether this effect of GH occurs directly or is
mediated by other factors, such as IGF-1. The extent of pituitary GH depletion that
must occur in order to eliminate its inhibitory effect on GRH gene expression is not
precisely known, though it is believed to be at least 75 percent.
Thyroid hormone deficiency also increases hypothalamic GRH mRNA levels and
decreases GRH peptide content to levels that are as pronounced as after hypophysecto-
my, though the changes require from one to two weeks post-thyroidectomy to become
evident and are maximal only after three to four weeks [27]. The effects are mediated
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through depletion ofpituitary GH rather than by a direct effect on the hypothalamus,
since treatment with GH, even in the presence ofcontinued hypothyroidism, markedly
decreases the elevated levels ofGRH mRNA and increases the levels ofGRH peptide
content.
TRANSGENIC hGRH MOUSE
A model ofGRH overproduction has been developed using the transgenic approach
in mice, in which a fusion gene (Fig. 3) consisting of the mouse metallothionein I
promoter linked to a human GRH "minigene" containing GRH exons 2-5 as well as
the second intron and the 3' non-coding region [28]. Transgenic mice exhibit markedly
elevated GH levels, a growth rate of up to twice normal, and massive pituitary
mMT-1 hGRH hGRH hGRH hGRH
5'Flanking Exon 2 Intron B Exons 3-5 3'Flanklng
+ Exon 1 (cDNA)
MOUSE MT-1 HUMAN GRH 'MINIGENE'
PROMOTER
FIG. 3. Schematic representation ofthe mouse metallothionein I-human
GRH fusion gene used for the production of GRH transgenic mice. The
mouse promoter was fused to a GRH "minigene" in which a portion of the
GRH gene was replaced by a GRH cDNA that eliminated two introns.
Modified from Hammer et al.[28]
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enlargement due to somatotroph hyperplasia. The mice are fertile and exhibit germline
gene expression, resulting in transmission ofthe gene as a simple Mendelian dominant.
Identification of hGRH mRNA was initially reported by Northern blotting in liver,
intestine, pancreas, kidney, and spleen. By use of more sensitive radioimmunoassay,
however, we have observed GRH immunoreactivity, as well, in pituitary, brain,
adrenal, gonads, heart, lung, and skeletal muscle [29]. By means of standard
immunohistochemistry and double label immunofluorescence, GRH has been identi-
fied in four separate cell types of the anterior pituitary (somatotrophs, lactotrophs,
gonadotrophs, and thyrotrophs), two cell types in the pancreatic islets (glucagon-
containing A cells and somatostatin-containing D cells), Brunner's glands of small
intestine, proximal convoluted tubules of the kidney, adrenal medulla, atrial cardio-
cytes, peribronchiolar epithelium, testicular Leydig cells, and oocytes [30]. In the
brain, hGRH was identified in neuronal perikarya of the arcuate nucleus, where the
hormone would normally be expected to occur, extensively concentrated in- the outer
layer ofthe median eminence, in the supraoptic nuclei, the paraventricular region, and
the amygdala. Although some of the tissues in which GRH is expressed also express
the metallothionein gene [31,32], some of the selectivity appears unique to GRH and
suggests that tissue-specific regulatory elements are present within the second intron,
the 3' end ofthe message, or possibly the coding region itself.
The widespread distribution of GRH suggests several possibilities by which the
releasing hormone could produce GH hypersecretion and somatotroph hyperplasia:
autocrine, paracrine, neuroendocrine, and endocrine. The specific contributions of
each possibility remain to be evaluated, though some clarification has been provided by
initial studies of the molecular heterogeneity of GRH in specific tissues. Using two
separate radioimmunoassay systems to measure GRH, one of which detects the
mid-portion of the molecule, and also carboxy terminally extended molecules (includ-
ing the GRH precursor), and the other ofwhich requires an amino terminus in the 44
position (and thus should not recognize the precursor), we have examined GRH
heterogeneity using multiple chromatography systems, including gel filtration and
reverse-phase high-performance liquid chromatography. Initial studies indicate that
the GRH precursor is present in multiple tissues and that the pituitary, pancreas, and
brain all appear capable of processing the precursor to the mature hormone, though
with varying degrees of effectiveness. Primary cultures of transgenic mouse pancreas
secrete multiple forms of immunoreactive GRH, and preliminary studies of GRH
biosynthesis using 35S-methionine incorporation indicate the presence of label in the
precursor form andGRH14OH, and possibly other forms as well. In contrast, the liver
is able to process the precursor partially, though incompletely. Nearly all GRH
immunoreactivity in plasma is in the form of GRH344NH2, indicating that the
mouse, like the rat and human, has an active dipeptidylpeptidase system and, despite
the extremely high levels of total GRH immunoreactivity, very little of it is in a
biologically active form. This finding suggests that the contribution of circulating
hormone to the overall development of GH overproduction is small. The source of the
hormone in plasma is still unknown and other transgenic models are now being
examined to provide more information.
SUMMARY
In the short period oftime since the first identification ofGRH in human tumors, its
structural forms have been identified and its gene has been cloned in several species, its
structural-functional relationships have been defined, its metabolism has been charac-
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terized, and considerable information has been generated concerning its gene regula-
tion. A model of GRH overproduction has been developed with similarities to the
disease that led to the isolation of GRH and which has permitted for the first time
studies of GRH biosynthesis. During the next few years, equally exciting data can be
expected concerning neuroendocrine mechanisms involved in the regulation ofits gene
expression, leading to enhanced understanding of its role in the control of growth
hormone secretion. In particular, the potential role of GRH in the pathogenesis of
dwarfism in both laboratory animals and man and in various states ofGH overproduc-
tion may be clarified and the development of agonist and antagonist analogs of the
hormone may provide new approaches to therapy of disorders of GRH under- and
overproduction.
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